201 related articles for article (PubMed ID: 23094915)
1. Recombinant snake venom cystatin inhibits tumor angiogenesis in vitro and in vivo associated with downregulation of VEGF-A165, Flt-1 and bFGF.
Xie Q; Tang N; Wan R; Qi Y; Lin X; Lin J
Anticancer Agents Med Chem; 2013 May; 13(4):663-71. PubMed ID: 23094915
[TBL] [Abstract][Full Text] [Related]
2. Recombinant snake venom cystatin inhibits the growth, invasion and metastasis of B16F10 cells and MHCC97H cells in vitro and in vivo.
Xie Q; Tang N; Wan R; Qi Y; Lin X; Lin J
Toxicon; 2011 Apr; 57(5):704-11. PubMed ID: 21329716
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of invasion and metastasis of MHCC97H cells by expression of snake venom cystatin through reduction of proteinases activity and epithelial-mesenchymal transition.
Tang N; Xie Q; Wang X; Li X; Chen Y; Lin X; Lin J
Arch Pharm Res; 2011 May; 34(5):781-9. PubMed ID: 21656364
[TBL] [Abstract][Full Text] [Related]
4. Recombinant adenovirus snake venom cystatin inhibits the growth, invasion, and metastasis of B16F10 cells in vitro and in vivo.
Xie Q; Tang N; Lin Y; Wang X; Lin X; Lin J
Melanoma Res; 2013 Dec; 23(6):444-51. PubMed ID: 24128788
[TBL] [Abstract][Full Text] [Related]
5. Rhodostomin, a snake venom disintegrin, inhibits angiogenesis elicited by basic fibroblast growth factor and suppresses tumor growth by a selective alpha(v)beta(3) blockade of endothelial cells.
Yeh CH; Peng HC; Yang RS; Huang TF
Mol Pharmacol; 2001 May; 59(5):1333-42. PubMed ID: 11306719
[TBL] [Abstract][Full Text] [Related]
6. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
7. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
8. Bastadin 6, a spongean brominated tyrosine derivative, inhibits tumor angiogenesis by inducing selective apoptosis to endothelial cells.
Aoki S; Cho SH; Ono M; Kuwano T; Nakao S; Kuwano M; Nakagawa S; Gao JQ; Mayumi T; Shibuya M; Kobayashi M
Anticancer Drugs; 2006 Mar; 17(3):269-78. PubMed ID: 16520655
[TBL] [Abstract][Full Text] [Related]
9. Jiedu Xiaozheng Yin, a Chinese herbal formula, inhibits tumor angiogenesis via downregulation of VEGF-A and VEGFR-2 expression in vivo and in vitro.
Cao Z; Lin W; Huang Z; Chen X; Zhao J; Zheng L; Ye H; Liu Z; Liao L; Du J
Oncol Rep; 2013 Mar; 29(3):1080-6. PubMed ID: 23254951
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic and Antitumor Activities of Aflibercept, a Soluble VEGF Receptor-1 and -2, in a Mouse Model of Hepatocellular Carcinoma.
Torimura T; Iwamoto H; Nakamura T; Abe M; Ikezono Y; Wada F; Sakaue T; Masuda H; Hashimoto O; Koga H; Ueno T; Yano H
Neoplasia; 2016 Jul; 18(7):413-24. PubMed ID: 27435924
[TBL] [Abstract][Full Text] [Related]
11. Norcantharidin: a potential antiangiogenic agent for gallbladder cancers in vitro and in vivo.
Zhang JT; Fan YZ; Chen CQ; Zhao ZM; Sun W
Int J Oncol; 2012 May; 40(5):1501-14. PubMed ID: 22200632
[TBL] [Abstract][Full Text] [Related]
12. Dual blockade of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2) exhibits potent anti-angiogenic effects.
Li D; Xie K; Zhang L; Yao X; Li H; Xu Q; Wang X; Jiang J; Fang J
Cancer Lett; 2016 Jul; 377(2):164-73. PubMed ID: 27130666
[TBL] [Abstract][Full Text] [Related]
13. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
Bae DG; Kim TD; Li G; Yoon WH; Chae CB
Clin Cancer Res; 2005 Apr; 11(7):2651-61. PubMed ID: 15814646
[TBL] [Abstract][Full Text] [Related]
14. SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.
Cao ZX; Zheng RL; Lin HJ; Luo SD; Zhou Y; Xu YZ; Zeng XX; Wang Z; Zhou LN; Mao YQ; Yang L; Wei YQ; Yu LT; Yang SY; Zhao YL
Cell Physiol Biochem; 2011; 27(5):565-74. PubMed ID: 21691074
[TBL] [Abstract][Full Text] [Related]
15. Tanshinone IIA inhibits β-catenin/VEGF-mediated angiogenesis by targeting TGF-β1 in normoxic and HIF-1α in hypoxic microenvironments in human colorectal cancer.
Sui H; Zhao J; Zhou L; Wen H; Deng W; Li C; Ji Q; Liu X; Feng Y; Chai N; Zhang Q; Cai J; Li Q
Cancer Lett; 2017 Sep; 403():86-97. PubMed ID: 28602978
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
Ciardiello F; Caputo R; Bianco R; Damiano V; Fontanini G; Cuccato S; De Placido S; Bianco AR; Tortora G
Clin Cancer Res; 2001 May; 7(5):1459-65. PubMed ID: 11350918
[TBL] [Abstract][Full Text] [Related]
17. Soluble production and function of vascular endothelial growth factor/basic fibroblast growth factor complex peptide.
Zhang Q; Lao X; Huang J; Zhu Z; Pang L; Tang Y; Song Q; Huang J; Deng J; Deng N; Yang Q; Sengupta AM; Xiong L
Biotechnol Prog; 2015; 31(1):194-203. PubMed ID: 25271020
[TBL] [Abstract][Full Text] [Related]
18. DDA suppresses angiogenesis and tumor growth of colorectal cancer in vivo through decreasing VEGFR2 signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Oncotarget; 2016 Sep; 7(39):63124-63137. PubMed ID: 27517319
[TBL] [Abstract][Full Text] [Related]
19. A BMP7 Variant Inhibits Tumor Angiogenesis In Vitro and In Vivo through Direct Modulation of Endothelial Cell Biology.
Tate CM; Mc Entire J; Pallini R; Vakana E; Wyss L; Blosser W; Ricci-Vitiani L; D'Alessandris QG; Morgante L; Giannetti S; Larocca LM; Todaro M; Benfante A; Colorito ML; Stassi G; De Maria R; Rowlinson S; Stancato L
PLoS One; 2015; 10(4):e0125697. PubMed ID: 25919028
[TBL] [Abstract][Full Text] [Related]
20. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY
Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]